Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 11/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25431540 | 0.91 | NLRP3 (0.52) | NLRP3KMT2AUSP2SMN1; SMN2TSHR | |
| SCHEMBL25331822 | 0.90 | NLRP3 (0.51) | NLRP3KMT2AUSP2MAPTSMN1; SMN2 | |
| SCHEMBL31325027 | 0.89 | NLRP3 (0.51) | NLRP3KMT2AUSP2SMN1; SMN2TSHR | |
| SCHEMBL31325023 | 0.87 | NLRP3 (0.62) | NLRP3KMT2AUSP2MAPTSMN1; SMN2 | |
| SCHEMBL31325035 | 0.85 | NLRP3 (0.59) | NLRP3KMT2AUSP2ALDH1A1HPGD | |
| SCHEMBL25430625 | 0.79 | NLRP3 (0.40) | NLRP3USP2SMN1; SMN2TSHRHTT | |
| SCHEMBL25332360 | 0.79 | ALOX15 (0.41) | NLRP3KMT2ATSHRHTTADORA2A | |
| SCHEMBL25332520 | 0.78 | NLRP3 (0.49) | NLRP3ADORA2AADORA1 | |
| SCHEMBL31325017 | 0.78 | NLRP3 (0.62) | NLRP3KMT2AUSP2MAPTGPR139 | |
| SCHEMBL24257264 | 0.77 | NLRP3 (1.00) | NLRP3KMT2AUSP2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066369-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2025-02-27 | — | — | US | disclosed |
| CN-118922421-A | Bicyclic phthalazin-1 (2H) -one derivatives and related uses | 诺瑟拉有限公司 | 2024-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066369-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | IL1B, NLRP3, IL1A | NLRP3 2/4885KMT2A 3863/4885USP2 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.